275 related articles for article (PubMed ID: 8669474)
1. Melanoma-associated expression of transforming growth factor-beta isoforms.
Van Belle P; Rodeck U; Nuamah I; Halpern AC; Elder DE
Am J Pathol; 1996 Jun; 148(6):1887-94. PubMed ID: 8669474
[TBL] [Abstract][Full Text] [Related]
2. Desensitization of melanoma cells to autocrine TGF-beta isoforms.
Krasagakis K; Krüger-Krasagakes S; Fimmel S; Eberle J; Thölke D; von der Ohe M; Mansmann U; Orfanos CE
J Cell Physiol; 1999 Feb; 178(2):179-87. PubMed ID: 10048582
[TBL] [Abstract][Full Text] [Related]
3. Expression of transforming growth factor-beta 2 in malignant melanoma correlates with the depth of tumor invasion. Implications for tumor progression.
Reed JA; McNutt NS; Prieto VG; Albino AP
Am J Pathol; 1994 Jul; 145(1):97-104. PubMed ID: 8030760
[TBL] [Abstract][Full Text] [Related]
4. In situ expression of transforming growth factor beta is associated with melanoma progression and correlates with Ki67, HLA-DR and beta 3 integrin expression.
Moretti S; Pinzi C; Berti E; Spallanzani A; Chiarugi A; Boddi V; Reali UM; Giannotti B
Melanoma Res; 1997 Aug; 7(4):313-21. PubMed ID: 9293481
[TBL] [Abstract][Full Text] [Related]
5. Expression of microtubule-associated protein 2 in benign and malignant melanocytes: implications for differentiation and progression of cutaneous melanoma.
Fang D; Hallman J; Sangha N; Kute TE; Hammarback JA; White WL; Setaluri V
Am J Pathol; 2001 Jun; 158(6):2107-15. PubMed ID: 11395388
[TBL] [Abstract][Full Text] [Related]
6. In situ analysis of transforming growth factor-beta s (TGF-beta 1, TGF-beta 2, TGF-beta 3), and TGF-beta type II receptor expression in malignant melanoma.
Schmid P; Itin P; Rufli T
Carcinogenesis; 1995 Jul; 16(7):1499-503. PubMed ID: 7614683
[TBL] [Abstract][Full Text] [Related]
7. Expression of the tumor suppressor gene product p16INK4 in benign and malignant melanocytic lesions.
Keller-Melchior R; Schmidt R; Piepkorn M
J Invest Dermatol; 1998 Jun; 110(6):932-8. PubMed ID: 9620301
[TBL] [Abstract][Full Text] [Related]
8. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
Elder DE; Rodeck U; Thurin J; Cardillo F; Clark WH; Stewart R; Herlyn M
Cancer Res; 1989 Sep; 49(18):5091-6. PubMed ID: 2548711
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical evidence of cytokine networks during progression of human melanocytic lesions.
Moretti S; Pinzi C; Spallanzani A; Berti E; Chiarugi A; Mazzoli S; Fabiani M; Vallecchi C; Herlyn M
Int J Cancer; 1999 Apr; 84(2):160-8. PubMed ID: 10096249
[TBL] [Abstract][Full Text] [Related]
10. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression.
Montone KT; van Belle P; Elenitsas R; Elder DE
Mod Pathol; 1997 Sep; 10(9):939-44. PubMed ID: 9310959
[TBL] [Abstract][Full Text] [Related]
11. Biology of tumor progression in human melanocytes.
Herlyn M; Clark WH; Rodeck U; Mancianti ML; Jambrosic J; Koprowski H
Lab Invest; 1987 May; 56(5):461-74. PubMed ID: 3553733
[TBL] [Abstract][Full Text] [Related]
12. Expression and structural features of endoglin (CD105), a transforming growth factor beta1 and beta3 binding protein, in human melanoma.
Altomonte M; Montagner R; Fonsatti E; Colizzi F; Cattarossi I; Brasoveanu LI; Nicotra MR; Cattelan A; Natali PG; Maio M
Br J Cancer; 1996 Nov; 74(10):1586-91. PubMed ID: 8932339
[TBL] [Abstract][Full Text] [Related]
13. Quantitative analysis of melanocytic tissue array reveals inverse correlation between activator protein-2alpha and protease-activated receptor-1 expression during melanoma progression.
Tellez CS; Davis DW; Prieto VG; Gershenwald JE; Johnson MM; McCarty MF; Bar-Eli M
J Invest Dermatol; 2007 Feb; 127(2):387-93. PubMed ID: 16946713
[TBL] [Abstract][Full Text] [Related]
14. Progression-related expression of beta3 integrin in melanomas and nevi.
Van Belle PA; Elenitsas R; Satyamoorthy K; Wolfe JT; Guerry D; Schuchter L; Van Belle TJ; Albelda S; Tahin P; Herlyn M; Elder DE
Hum Pathol; 1999 May; 30(5):562-7. PubMed ID: 10333228
[TBL] [Abstract][Full Text] [Related]
15. Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study.
Nazarian RM; Prieto VG; Elder DE; Duncan LM
J Cutan Pathol; 2010 Apr; 37 Suppl 1():41-7. PubMed ID: 20482674
[TBL] [Abstract][Full Text] [Related]
16. Heat shock protein 27 is expressed in normal and malignant human melanocytes in vivo.
Kang SH; Fung MA; Gandour-Edwards R; Reilly D; Dizon T; Grahn J; Isseroff RR
J Cutan Pathol; 2004 Nov; 31(10):665-71. PubMed ID: 15491326
[TBL] [Abstract][Full Text] [Related]
17. Expression of CD44 splice variants in human cutaneous melanoma and melanoma cell lines is related to tumor progression and metastatic potential.
Manten-Horst E; Danen EH; Smit L; Snoek M; Le Poole IC; Van Muijen GN; Pals ST; Ruiter DJ
Int J Cancer; 1995 Jun; 64(3):182-8. PubMed ID: 7542641
[TBL] [Abstract][Full Text] [Related]
18. Cyclin D1 expression in melanocytic lesions of the skin.
Ramirez JA; Guitart J; Rao MS; Diaz LK
Ann Diagn Pathol; 2005 Aug; 9(4):185-8. PubMed ID: 16084449
[TBL] [Abstract][Full Text] [Related]
19. Divergent cellular differentiation pathways during the invasive stage of cutaneous malignant melanoma progression.
Reed JA; Finnerty B; Albino AP
Am J Pathol; 1999 Aug; 155(2):549-55. PubMed ID: 10433947
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of basic fibroblast growth factor (bFGF) in melanocytic lesions demonstrated by in situ hybridization. Implications for tumor progression.
Reed JA; McNutt NS; Albino AP
Am J Pathol; 1994 Feb; 144(2):329-36. PubMed ID: 8311116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]